N@N

BLUD, NVO, RBN, ROS, SNY, CPII. Abnormal Price Friction In Morning Trading Session Today

^{Published on 2009-06-26 07:55:09, Last Modified on 2010-12-22 14:18:14 - WOPRAI}
 

June 26, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 26, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This fair market making requirement is designed to prevent market makers from manipulating stock prices. Here is a list of the companies with Abnormal Price Friction (unfair market) in their stock prices in today�s trading session. This means that there was more buying than selling in the stocks and their stock prices dropped. Immucor (NASDAQ: BLUD), Novo Nordisk (NYSE: NVO), Robbins & Myers (NYSE: RBN), Rostelecom (NYSE: ROS), Sanofi-Aventis (NYSE: SNY) and CPI International (NASDAQ: CPII). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

BLUD -$3.26 -20.26% 2,153,107 52.22% 1,894,433 45.95% 258,674 abnormal

NVO -$2.40 -4.55% 213,771 57.67% 79,342 21.40% 134,429 abnormal

RBN -$2.01 -9.37% 177,061 37.69% 169,602 36.10% 7,459 abnormal

ROS -$1.58 -4.95% 15,909 45.26% 13,120 37.33% 2,789 abnormal

SNY -$1.45 -4.80% 1,861,388 51.85% 1,147,777 31.97% 713,611 abnormal

CPII -$1.01 -9.87% 4,757 51.08% 4,556 48.92% 201 abnormal

Click here to view chart:

Analysis of the Friction Factor chart above shows that each of the stocks mentioned above had more buying than selling on Friday, June 26th, 2009 and their stock prices dropped. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows BLUD with 258,674 greater shares of buying than selling (NetVol) and the stock price is down -$3.26. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more buying than selling should cause prices to rise.

Immucor, Inc. (NASDAQ: BLUD), together with its subsidiaries, engages in the development, manufacture, and sale of various reagents and automated systems. Its products are used primarily by hospitals, clinical laboratories, and blood banks. The company�s reagent products include ABO blood grouping and Rh blood typing reagents, anti-human globulin serums, reagent red blood cells, rare serums, antibody potentiators, quality control systems, monoclonal antibody-based reagents, technical proficiency systems, and fetal bleed screen kit, as well as Capture-P, Capture-R, Capture-CMV, Capture-S, and Capture-R Select reagents. Its reagents are used in tests performed prior to blood transfusion in the determination of the blood group and type of patient and donor blood; in the detection and identification of blood group antibodies; and in platelet antibody detection and in prenatal care. The company also offers various instruments and instrument systems, which include Galileo, an automated solution to perform routine blood bank tests; Galileo Echo, a compact bench top automated instrument for small- and medium-sized hospitals, blood banks, and transfusion laboratories; and Capture Workstation, which has semi-automated components for performing Capture assays manually. Immucor sells its products through sales, marketing, and distribution personnel in the United States, Canada, Europe, and Japan, as well as through sales agents in Italy. The company was founded in 1982 and is based in Norcross, Georgia.

Novo Nordisk A/S (NYSE: NVO), a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulin franchise, including modern insulins, human insulins, insulin-related sales, and oral antidiabetic drugs, as well as GLP-1 compounds in development for both the treatment of type 2 diabetes and as an anti-obesity agent. The Biopharmaceuticals segment provides products in the areas of haemostasis management, growth hormone therapy, hormone replacement therapy, inflammation therapy, and other therapy areas. The company sells its products principally in the United States, Japan, China, the Russian Federation, India, Turkey, and other European countries. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Robbins & Myers, Inc. (NYSE: RBN), together with its subsidiaries, supplies engineered equipment and systems for various applications in energy, industrial, chemical, and pharmaceutical markets worldwide. The company operates in three segments: Fluid Management, Process Solutions, and Romaco. The Fluid Management segment engages in the design, manufacture, and marketing of equipment and systems used in oil and gas exploration and recovery, specialty chemical, wastewater treatment, and various other industrial applications. Its products and systems include hydraulic drilling power sections; down-hole and industrial progressing cavity pumps and related products, such as grinders for applications involving the flow of viscous, abrasive, and solid-laden slurries and sludge; and a line of ancillary equipment, including rod guides, rod and tubing rotators, wellhead systems, pipeline closure products, and valves. The Process Solutions segment designs, manufactures, and services glass-lined reactors and storage vessels, fluid-agitation equipment and systems, thermal fluid systems and fluoropolymer-lined fittings, and vessels and accessories primarily for the pharmaceutical and fine chemical markets. The Romaco segment involves in the design, manufacture, and marketing of packaging and secondary processing equipment for the pharmaceutical, healthcare, nutriceutical, food, and cosmetic industries. Its packaging applications include dosing, filling, and sealing of vials, capsules, tubes, bottles, and blisters, as well as customized packaging. Robbins & Myers sells its products and systems through direct sales force, distributors, manufacturer representatives, and third party distributors, as well as through service centers. The company was founded in 1878 and is based in Dayton, Ohio.

OAO Rostelecom (NYSE: ROS), together with its subsidiaries, provides domestic and international long-distance telecommunications services to the government, businesses, and individuals in the Russian Federation. It provides switching and transmission infrastructure that connects the Russian domestic telecommunications trunk network with foreign networks and, in coordination with foreign telecommunications operators, facilitate the transmission of telecommunications traffic in the Russian Federation; and domestic long distance traffic. The company also offers voice traffic interconnection and transmission, signaling traffic transit interconnection and transmission, integrated services digital network traffic transmission, connection to its synchronization network, telegraph traffic transmission, local telephone, backbone Internet access, Internet protocol traffic interconnection and transmission, virtual private network, data center, domestic long-distance and international rent of channels, videoconferencing, audio conferencing, and intelligent network services. It offers its services through ground and submarine cables, digital radio-relay lines, and satellites. The company has international fiber optic links (FOLs) accessing Finland, Denmark, Turkey, Italy, Bulgaria, Japan, Korea, China, Estonia, Kazakhstan, Ukraine, Georgia, and Belarus. As of December 31, 2008, its digital network comprised 49,987 kilometers, including 35,291 kilometers of FOLs and 14,696 kilometers of digital radio-relay lines. The company was founded in 1993 and is headquartered in Moscow, the Russian Federation. OAO Rostelecom is a subsidiary of OAO Svyazinvest.

Sanofi-Aventis (NYSE: SNY), a pharmaceutical company, contributes to enhancing life by providing an offering of medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company has products in the areas of thrombosis, cardiovascular, metabolic diseases, oncology, central nervous system, internal medicine, and vaccines. Its primary medicines include Lovenox/Clexane, Plavix/Iscover, Aprovel/Avapro/Karvea, Tritace/Triatec/Delix/Altace, Lantus, Amaryl/Amarel/Solosa, Acomplia, Taxotere, Eloxatine, Stilnox/Ambien/Myslee, Copaxone, Depakine, Allegra/Telfast, Nasacort, Xatral/Uroxatral, and Actonel/Optinate/Acrel. The company�s vaccines principally include pediatric combination and poliomyelitis vaccines, influenza vaccines, meningitis/pneumonia vaccines, adult and adolescent booster vaccines, and travel and endemic vaccines. It has collaboration agreements principally with Novozymes, Dyax Corp., Oxford BioMedica, Regeneron, IDM, Zealand Pharma, UCB, and Crucell N.V., as well as partners, including Immunogen, Coley, Wayne State University, Innogenetics, and Inserm. The company also has an agreement with Drugs For Neglected Diseases Initiative (dndi) for the development, manufacturing, and distribution of fexinidazole, a drug for the treatment of human African trypanosomiasis. Sanofi-Aventis was founded in 1970 and is headquartered in Paris, France.

CPI International, Inc. (NASDAQ: CPII), through its subsidiaries, provides microwave and radio frequency (RF), power, and control products primarily in the United States. The company operates in two segments, VED and Satcom Equipment. The VED segment develops, manufactures, and distributes high power/high frequency microwave and RF signal components. Its products include linear beam, cavity, power grid, crossed field, and magnetron devices. The Satcom Equipment segment manufactures and supplies high power amplifiers and networks for satellite communication uplink and industrial applications. It also provides spares, service, and other post sales support. The company�s products are used for defense, communications, medical, scientific, and other applications to generate, amplify, transmit, and receive high-power microwave and RF signals and provide power and control for various applications. It distributes its products through its direct sales force and independent sales representatives. CPI International, Inc., formerly known as CPI Holdco, Inc., was founded in 1948. It changed its name to CPI International, Inc. in 2006. The company is headquartered in Palo Alto, California.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,600,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net